CXCR4 antagonists for wound healing and re-epithelialization

Patent metadata

Field	Value
Publication number	US-9034814-B2
Application number	US-91542806-A
Country	US
Kind code	B2
Filing date	May 21, 2006
Priority date	May 25, 2005
Publication date	May 19, 2015
Grant date	May 19, 2015

Abstract

The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialization in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.

First claim

The invention claimed is:

1. A method of promoting wound healing in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a CXCR4 inhibitor wherein said CXCR4 inhibitor is a peptide having the amino acid sequence set forth in any one of SEQ ID NOS: 1-68 and 70-71, wherein the wound is a partial thickness dermal wound.

2. The method of claim 1 , wherein the peptide is selected from the group consisting of SEQ ID NOS: 1-3, 9, 45, 46, 50-56, 65, 66, 68, 70 and 71.

3. The method of claim 1 , wherein the peptide is selected from the group consisting of SEQ ID NOS: 3, 9, 45, 46, 68 and 70.

4. The method of claim 1 , wherein the peptide is selected from the group consisting of SEQ ID NOS: 1, 50, 52, 65 and 66.

5. The method of claim 1 , wherein the peptide is selected from the group consisting of SEQ ID NOS: 53-56.

6. The method of claim 1 , wherein the peptide is SEQ ID NO:65.

7. The method of claim 1 , wherein the peptide is SEQ ID NO: 52.

8. The method of claim 1 , wherein the wound is a dermal burn.

9. The method of claim 1 for the reduction of scarring in said subject.

10. The method of claim 1 , wherein said subject is in need of improved epithelialization.

11. The method of claim 1 , wherein said subject is need of inhibited fibrosis.

12. The method of claim 1 wherein the pharmaceutical composition is administered to said subject in a manner selected from the group consisting of: topically, intralesionally, transdermally, subcutaneously, intravenously, intrarectally and orally.

13. The method of claim 1 , wherein the composition is a topical pharmaceutical composition.

14. The method of claim 1 , wherein the composition consists essentially of said CXCR4 inhibitor.

15. The method of claim 13 , wherein the composition consists essentially of said CXCR4 inhibitor.

16. A method of treating wounds in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a CXCR4 inhibitor, wherein said CXCR4 inhibitor is a peptide having the amino acid sequence set forth in any one of SEQ ID NOS: 1-68 and 70-71, and wherein the wounds are selected from the group consisting of burn wounds, pressure sores, venous stasis ulcers and diabetic ulcers.

17. The method of claim 10 wherein said subject is in need of improved epithelialization and inhibited fibrosis.

18. The method of claim 10 wherein said subject is in need of reduced scarring.

Assignees

• Peled Amnon
• Fujii Nobutaka
• Hadasit Med Res Service
• Univ Kyoto

Inventors

• Peled Amnon
• Fujii Nobutaka

Classifications

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61K38/04 Primary

  Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55}) · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title